The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism

Journal of Translational Medicine

Volumn 14, Issue 1, 2016, Pages

  Andreozzi, Francesco ^a,b   Raciti, Gregory Alexander ^c,d   Nigro, Cecilia ^c,d   Mannino, Gaia Chiara ^a   Procopio, Teresa ^a   Davalli, Alberto M ^e   Beguinot, Francesco ^c,d   Sesti, Giorgio ^a   Miele, Claudia ^c,d   Folli, Franco ^b,f  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c CNR   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

AMPK; Exenatide; Glucose uptake; Insulin signaling; Liraglutide; Skeletal muscle cells

Indexed keywords

DEOXYGLUCOSE; EXENDIN 4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; JANUS KINASE 1; JANUS KINASE 2; LIRAGLUTIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN P85; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; METHYLGLYOXAL; PEPTIDE; PROTEIN KINASE B; VENOM;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; GLUCOSE TRANSPORT; INTRACELLULAR SIGNALING; MOLECULAR DYNAMICS; MYOTUBE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SKELETAL MUSCLE CELL; AGONISTS; ANIMAL; BABOON; CELL LINE; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENE SILENCING; HUMAN; INSULIN RESISTANCE; METABOLISM; MOUSE; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TIME FACTOR; TRANSPORT AT THE CELLULAR LEVEL;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE; DEOXYGLUCOSE; ENZYME ACTIVATION; GENE EXPRESSION PROFILING; GENE SILENCING; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCOSE; HUMANS; INSULIN RESISTANCE; LIRAGLUTIDE; MICE; MUSCLE FIBERS, SKELETAL; PAPIO; PEPTIDES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PYRUVALDEHYDE; RATS; SIGNAL TRANSDUCTION; TIME FACTORS; VENOMS;

EID: 84979705690     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-016-0985-7     Document Type: Article

References (55)

1. Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest. 1987;79:616-9.
2. Schmidt WE, Siegel EG, Creutzfeldt W. Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia. 1985;28:704-7.
3. Fehse F, Trautmann M, Holst JJ, Halseth AE, Nanayakkara N, Nielsen LL, et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2005;90:5991-7.
4. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17:819-37.
5. Crisci I, Aragona A, Politi KS, Daniele G, Del Prato S. GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach. Acta Diabetol. 2015;52:1129-33.
6. Sarkar G, Alattar M, Brown RJ, Quon MJ, Harlan DM, Rother KI. Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes Care. 2014;37:666-70.
7. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes. 1999;48:1026-34.
8. Gutniak M, Orskov C, Holst JJ, Ahrén B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med. 1992;326:1316-22.
9. Cervera A, Wajcberg E, Sriwijitkamol A, Fernandez M, Zuo P, Triplitt C, et al. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab. 2008;294:E846-52.
10. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA. 1992;89:8641-5.
11. Briaud I, Lingohr MK, Dickson LM, Wrede CE. Rhodes CJ (2003) Differential activation mechanisms of Erk-1/2 and p70(S6 K) by glucose in pancreatic beta-cells. Diabetes. 1992;52:974-83.
12. Arnette D, Gibson TB, Lawrence MC, January B, Khoo S, McGlynn K, et al. Regulation of ERK1 and ERK2 by glucose and peptide hormones in pancreatic beta cells. J Biol Chem. 2003;278:32517-25.
13. Villanueva-Peñacarrillo ML, Puente J, Redondo A, Clemente F, Valverde I. Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in type 1 and type 2 rat diabetic models. Endocrine. 2001;15:241-8.
14. Idris I, Patiag D, Gray S, Donnelly R. Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: contrasting effects of GLP-1. Biochem Pharmacol. 2002;63:993-6.
15. González N, Acitores A, Sancho V, Valverde I, Villanueva-Peñacarrillo ML. Effect of GLP-1 on glucose transport and its cell signalling in human myocytes. Regul Peptide. 2005;126:203-11.
16. Green CJ, Henriksen TI, Pedersen BK, Solomon TP. Glucagon like peptide-1-induced glucose metabolism in differentiated human muscle satellite cells is attenuated by hyperglycemia. PLoS ONE. 2012;7:e44284.
17. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13:251-62.
18. Taylor EB, An D, Kramer HF, Yu H, Fujii NL, Roeckl KS, et al. Discovery of TBC1D1 as an insulin-, AICAR-, and contraction-stimulated signaling nexus in mouse skeletal muscle. J Biol Chem. 2008;283(15):9787-96.
19. Jessen N, An D, Lihn AS, Nygren J, Hirshman MF, Thorell A, et al. Exercise increases TBC1D1 phosphorylation in human skeletal muscle. Am J Physiol Endocrinol Metab. 2011;301(1):E164-71.
20. Funai K, Schweitzer GG, Sharma N, Kanzaki M, Cartee GD. Increased AS160 phosphorylation, but not TBC1D1 phosphorylation, with increased postexercise insulin sensitivity in rat skeletal muscle. Am J Physiol Endocrinol Metab. 2009;297(1):E242-51.
21. Dokas J, Chadt A, Nolden T, Himmelbauer H, Zierath JR, Joost HG, et al. Conventional knockout of Tbc1d1 in mice impairs insulin- and AICAR-stimulated glucose uptake in skeletal muscle. Endocrinology. 2013;154(10):3502-14.
22. Koistinen HA, Galuska D, Chibalin AV, Yang J, Zierath JR, Holman GD, et al. 5-amino-imidazole carboxamide riboside increases glucose transport and cell-surface GLUT4 content in skeletal muscle from subjects with type 2 diabetes. Diabetes. 2003;52:1066-72.
23. Widmann C, Bürki E, Dolci W, Thorens B. Signal transduction by the cloned glucagon-like peptide-1 receptor: comparison with signaling by the endogenous receptors of beta cell lines. Mol Pharmacol. 1994;45:1029-35.
24. Hribal ML, Federici M, Porzio O, Lauro D, Borboni P, Accili D, et al. The Gly- > Arg972 amino acid polymorphism in insulin receptor substrate-1 affects glucose metabolism in skeletal muscle cells. J Clin Endocrinol Metab. 2000;85:2004-13.
25. Condorelli G, Vigliotta G, Trencia A, Maitan MA, Caruso M, Miele C, et al. Protein kinase C (PKC)-alpha activation inhibits PKC-zeta and mediates the action of PED/PEA-15 on glucose transport in the L6 skeletal muscle cells. Diabetes. 2001;50:1244-52.
26. Cassese A, Esposito I, Fiory F, Barbagallo AP, Paturzo F, Mirra P, et al. In skeletal muscle advanced glycation end products (AGEs) inhibit insulin action and induce the formation of multimolecular complexes including the receptor for AGEs. J Biol Chem. 2008;283:36088-99.
27. Huang C, Thirone AC, Huang X, Klip A. Differential contribution of insulin receptor substrates 1 versus 2 to insulin signaling and glucose uptake in L6 myotubes. J Biol Chem. 2005;280:19426-35.
28. Chavez AO, Lopez-Alvarenga JC, Tejero ME, Triplitt C, Bastarrachea RA, Sriwijitkamol A, et al. Physiological and molecular determinants of insulin action in the baboon. Diabetes. 2008;57:899-908.
29. Tripathy D, Daniele G, Fiorentino TV, Perez-Cadena Z, Chavez-Velasquez A, Kamath S, et al. Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3 TACE dyad in type 2 diabetes mellitus. A randomised double blind-placebo controlled mechanistic study. Diabetologia. 2013;56:2153-63.
30. Teitelman G, Alpert S, Hanahan D. Proliferation, senescence, and neoplastic progression of beta cells in hyperplasic pancreatic islets. Cell. 1988;52:97-105.
31. Nigro C, Raciti GA, Leone A, Fleming TH, Longo M, Prevenzano I, et al. Methylglyoxal impairs endothelial insulin sensitivity both in vitro and in vivo. Diabetologia. 2014;57:1485-94.
32. Federici M, Hribal M, Perego L, Ranalli M, Bonini P, Caradonna Z, et al. High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death program. Diabetes. 2001;50:1290-301.
33. Guardado-Mendoza R, Davalli AM, Chavez AO, Hubbard GB, Dick EJ, Majluf-Cruz A, et al. Pancreatic islet amyloidosis, beta cell apoptosis and alpha cell proliferation are determinants of islet remodeling in type 2 diabetic baboons. Proc Natl Acad Sci. 2009;106:13992-7.
34. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-35.
35. Smits MM, Tonneijck L, Muskiet MH, Kramer MH, Diamant M, Pieters-van den Bos IC, et al. GLP-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in type 2 diabetes patients: a randomised trial. Diabetes Obes Metab. 2015;18(3):281-8.
36. Egan JM, Montrose-Rafizadeh C, Wang Y, Bernier M, Roth J. Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action. Endocrinology. 1994;135(5):2070-5.
37. Oben J, Morgan L, Fletcher J, Marks V. Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36) amide, on fatty acid synthesis in explants of rat adipose tissue. J Endocrinol. 1991;130(2):267-72.
38. Miki H, Namba M, Nishimura T, Mineo I, Matsumura T, Miyagawa J, et al. Glucagon-like peptide-1(7-36)amide enhances insulin-stimulated glucose uptake and decreases intracellular cAMP content in isolated rat adipocytes. Biochim Biophys Acta. 1996;1312(2):132-6.
39. Yang H, Egan JM, Wang Y, Moyes CD, Roth J, Montrose MH, et al. GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1receptor. Am J Physiol. 1998;275(3 Pt 1):C675-83.
40. Galera C, Clemente F, Alcantara A, Trapote MA, Perea A, Lopez-Delgado MI, et al. Inositolphosphoglycans and diacyglycerol are possible mediators in the glycogenic effect of GLP-1(7-36)amide in BC3H-1 myocytes. Cell Biochem Funct. 1996;14(1):43-8.
41. Alcántara AI, Morales M, Delgado E, López-Delgado MI, Clemente F, Luque MA, et al. Exendin-4 agonist and exendin(9-39)amide antagonist of the GLP-1(7-36)amide effects in liver and muscle. Arch Biochem Biophys. 2014;341(1):1-7.
42. Wu H, Sui C, Xu H, Xia F, Zhai H, Zhang H, et al. The GLP-1 analogue exenatide improves hepatic and muscle insulin sensitivity in diabetic rats: tracer studies in the basal state and during hyperinsulinemic-euglycemic clamp. J Diabetes Res. 2014;2014:524517.
43. Moreno P, Nuche-Berenguer B, Gutiérrez-Rojas I, Acitores A, Sancho V, Valverde I, et al. Normalizing action of exendin-4 and GLP-1 in the glucose metabolism of extrapancreatic tissues in insulin-resistant and type 2 diabetic states. J Mol Endocrinol. 2012;48(1):37-47.
44. Ayala JE, Bracy DP, James FD, Julien BM, Wasserman DH, Drucker DJ. The glucagon-like peptide 1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. Endocrinology. 2009;150:1155-64.
45. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007;408(3):297-315.
46. Bijland S, Mancini SJ, Salt IP. Role of AMP-activated protein kinase in adipose tissue metabolism and inflammation. Clin Sci (Lond). 2013;124:491-507.
47. Procopio C, Andreozzi F, Laratta E, Cassese A, Beguinot F, Arturi F, et al. Leptin-stimulated endothelial nitric-oxide synthase via an adenosine 5'-monophosphate-activated protein kinase/Akt signaling pathway is attenuated by interaction with C-reactive protein. Endocrinology. 2009;150:3584-93.
48. Zachariah Tom R, Garcia-Roves PM, Sjögren RJ, Jiang LQ, Holmström MH, Deshmukh AS, et al. effects of AMPK activation on insulin sensitivity and metabolism in leptin-deficient ob/ob mice. Diabetes. 2014;63:1560-7.
49. Lee JO, Lee SK, Kim JH, Kim N, You GY, Moon JW, et al. Translocation through AMP-activated Protein Kinase (AMPK)-mediated Cbl/CAP Signaling in 3T3-L1 Preadipocyte Cells. J Biol Chem. 2012;287:44121-9.
50. Jensen TE, Schjerling P, Viollet B, Wojtaszewski JF, Richter EA. AMPK alpha1 activation is required for stimulation of glucose uptake by twitch contraction, but not by H2O2, in mouse skeletal muscle. PLoS ONE. 2008;3:e2102.
51. Koska J, Sands M, Burciu C, D'Souza KM, Raravikar K, Liu J, et al. Exenatide protects against glucose and lipid-induced endothelial dysfunction: evidence for direct vasodilation Effect of GLP-1 receptor agonists in humans. Diabetes. 2015;64:2624-35.
52. Han L, Yu Y, Sun X, Wang B. Exendin-4 directly improves endothelial dysfunction in isolated aortas from obese rats through the cAMP or AMPK-eNOS pathways. Diabetes Res Clin Pract. 2012;97:453-60.
53. Vyas AK, Yang KC, Woo D, Tzekov A, Kovacs A, Jay PY, et al. Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy. PLoS ONE. 2011;6:e17178.
54. Yamazaki S, Satoh H, Watanabe T. Liraglutide enhances insulin sensitivity by activating AMP-activated protein kinase in male Wistar rats. Endocrinology. 2014;155(9):3288-301.
55. Li Z, Ni CL, Yao Z, Chen LM, Niu WY. Liraglutide enhances glucose transporter 4 translocation via regulation of AMP-activated protein kinase signaling pathways in mouse skeletal muscle cells. Metabolism. 2014;63(8):1022-30.